# Biogen (BIIB) Q2 2026 earnings

Results filed 2026-07-29 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/biib/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/0000875045-26-000073-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Biogen's Growth Portfolio now outsells its legacy MS franchise after the Apellis acquisition, as management pivots toward a run of late-stage pipeline readouts beginning with lupus data by year-end.

Biogen's mix shifted toward newer products. Growth Portfolio revenue of $1.06 billion exceeded the legacy MS portfolio. The Apellis acquisition closed on May 14, 2026, adding SYFOVRE and EMPAVELI. SPINRAZA's high-dose regimen is converting faster than expected, SKYCLARYS is expanding in Europe, and ZURZUVAE launched in Germany. The FDA approved LEQEMBI IQLIK, an at-home initiation dose.
Management is steering toward a multi-year registrational cycle, with five late-stage readouts expected over the next four quarters, starting with litifilimab in lupus (SLE) by the end of 2026. It is also adding early-stage programs through the pending RayThera deal. The main tension is that the pipeline must deliver as the legacy MS business declines and Apellis financing weighs on earnings.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenue | $2,736 | up 3% from a year ago | GAAP |
| Net income attributable to Biogen | $97.5 | down from $634.8 million a year ago | GAAP |
| Diluted EPS | $0.66 | down 85% from a year ago | GAAP |
| Non-GAAP diluted EPS | $3.60 | down 34% from a year ago | non-GAAP |
| Net cash flow from operations | $448.9 | up from $160.9 million a year ago | GAAP |
| Free cash flow | $408.0 | up from $134.3 million a year ago | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| SPINRAZA | $402 million | up 2% year-over-year |
| LEQEMBI global in-market sales | $184 million | up 15% year-over-year |
| SKYCLARYS | $168 million | up 29% year-over-year |
| ZURZUVAE | $71 million | up 53% year-over-year |
| SYFOVRE (full quarter) | $162 million | up 8% year-over-year |
| EMPAVELI (full quarter) | $46 million | up 123% year-over-year |
| VUMERITY | $197 million | down 7% year-over-year |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Underlying non-GAAP diluted EPS | full year 2026 | $15.85 to $16.85 |
| Reported non-GAAP diluted EPS | full year 2026 | $12.00 to $13.00 |
| Combined non-GAAP R&D and SG&A expense | second half of 2026 | $2.65 billion and $2.70 billion |
| Apellis dilution to non-GAAP EPS | full year 2026 | approximately $0.85 |

## Key takeaways

1. **Growth Portfolio now outsells legacy MS franchise** Growth Portfolio revenue of $1.06 billion grew 24% year-over-year and exceeded the legacy MS portfolio. This marks the shift in Biogen's commercial base toward newer products.
2. **Apellis adds SYFOVRE and EMPAVELI to the portfolio** The acquisition closed May 14, 2026, and SYFOVRE posted its strongest quarterly demand since launch. EMPAVELI grew 123% for the full quarter, and management expects at least $250 million of run rate synergies exiting 2027.
3. **SPINRAZA high-dose conversion is ahead of expectations** Conversion to the high-dose regimen is ahead of company expectations in all launched geographies, supporting SPINRAZA's franchise. The release calls the SPINRAZA HD launch successful.
4. **LEQEMBI IQLIK approval enables at-home initiation** The FDA approved IQLIK as an initiation dose, described as a first-of-its-kind anti-amyloid at-home option. LEQEMBI global in-market sales were $184 million, up 15%, with U.S. sales of $97 million growing sequentially.
5. **Five registrational readouts start with lupus data** Litifilimab in SLE reports by end of 2026, with litifilimab in CLE, felzartamab in AMR and zorevunersen in Dravet syndrome next year. Diranersen showed proof-of-concept in Alzheimer's as the first tau-directed agent to show clinical efficacy, and Biogen plans Phase 3.

## Questions

**What did Biogen launch or get approved this quarter?** The FDA approved LEQEMBI IQLIK as an at-home initiation dose, and the SPINRAZA high-dose regimen launched with conversion ahead of expectations. ZURZUVAE also launched in Germany, its first commercial launch outside the U.S. for postpartum depression.
**How is the Apellis acquisition performing?** SYFOVRE had its strongest quarterly demand since launch and EMPAVELI grew 123% for the full quarter. Biogen expects at least $250 million of run rate synergies exiting 2027 and accretion to Non-GAAP EPS in 2027.
**Which pipeline readouts are coming next?** Litifilimab in SLE is expected by end of 2026. Litifilimab in CLE, felzartamab in AMR and zorevunersen in Dravet syndrome follow next year.
**What is happening with Biogen's multiple sclerosis business?** MS product revenue fell 13% year-over-year, while the legacy MS portfolio held up on resilient TYSABRI performance. BIIB091 showed Phase 2 proof-of-concept in relapsing-remitting MS, and Biogen is exploring next steps.
**What new programs and deals did Biogen add?** Biogen exercised its option on Ionis's BIIB147 for ALS and has a pending RayThera acquisition that adds immunology programs. It also plans a new Phase 2 felzartamab study in Graves' disease.

